The Technical Analyst
Theratechnologies Inc [THTX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Theratechnologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.76% $1.310
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 60.23 mill |
| EPS: | -0.910 |
| P/E: | -1.440 |
| Earnings Date: | Jul 10, 2024 |
| SharesOutstanding: | 45.98 mill |
| Avg Daily Volume: | 0.0551 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.440 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -1.440 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.195 - 1.425 ( +/- 8.78%) |
| ATR Model: 14 days |
Forecast:
16:00 - $1.310
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.310
Forecast 2: 16:00 - $1.310
Forecast 3: 16:00 - $1.310
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.310 (-0.76% ) |
| Volume | 0.0104 mill |
| Avg. Vol. | 0.0551 mill |
| % of Avg. Vol | 18.92 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For THTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
THTX
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 16:15:00 - Press Release
Theratechnologies Announces Mailing Of Management Proxy Circular In Connection With Its Annual Meeting Of Shareholders
Montreal, april 15, 2024 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the company has mailed its 2024 management proxy circular to shareholders in connection with its virtual annual meeting of shareholders to be held on may 9, 2024, at 10:00 a.m. et.
2024-04-11 07:30:00 - Press Release
Theratechnologies To Present At The 2024 Bloom Burton & Co. Healthcare Investor Conference
Montreal, april 11, 2024 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the company's president and ceo, paul lÉvesque will be presenting at the 2024 bloom burton & co. healthcare investor conference, which is taking place april 16-17 in toronto, canada.
2024-04-10 07:30:00 - Press Release
Theratechnologies Reports Financial Results and Provides Business Update For First Quarter 2024
Montreal, april 10, 2024 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter of fiscal year 2024 ended february 29, 2024 (q1 2024). all figures are in us dollars unless otherwise stated.
2024-04-08 16:30:00 - Press Release
Theratechnologies Preclinical Data Presentation At Aacr 2024 Highlights Versatility And Flexibility Of Sort1+ Technology™ Oncology Platform
Montreal, april 08, 2024 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the company's sort1+ technology™ platform. in a poster session at the 2024 annual meeting of the american association for cancer research (aacr) in san diego, calif., researchers reported that theratechnologies' investigational camptothecin-peptide conjugates are well tolerated and associated with significant tumor regression in colorectal cancer (crc) and triple-negative breast cancer (tnbc) xenograft models...
2024-04-05 11:00:00 - Press Release
Theratechnologies Appoints Elina Tea To Its Board Of Directors
Montreal, april 05, 2024 (globe newswire) -- theratechnologies inc. (“theratechnologies” or the “company”) (tsx: th) (nasdaq: thtx), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of elina tea, chief financial officer at gls north america, to its board of directors and as a member of the company's audit committee. ms. tea will be investissement quÉbec's designee pursuant to its investor rights agreement with the company.
Latest News
2024-04-11 07:30:00 - GlobeNewsWire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 11, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company's President and CEO, Paul Lévesque will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is taking place April 16-17 in Toronto, Canada.
2024-04-03 07:30:00 - GlobeNewsWire
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its first quarter ended February 29, 2024, on Wednesday, April 10 at 8:30 a.m. ET.
2024-03-28 07:30:00 - GlobeNewsWire
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, demonstrating the potential of its SORT1+ Technology™ platform – including novel camptothecin-peptide conjugates and its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), as anticancer treatments. The AACR meeting is taking place April 5-10 in San Diego, CA.
2024-02-26 09:51:19 - Zacks Investment Research
Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain Stock
Theratechnologies (THTX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
2024-02-06 07:30:00 - GlobeNewsWire
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT.
2023-10-26 09:11:49 - InvestorPlace
Why Is Theratechnologies (THTX) Stock Down 22% Today?
Theratechnologies (NASDAQ: THTX ) stock is dropping on Thursday after the biopharmaceutical company announced a proposed public share offering. Theratechnologies is selling 12.5 million shares of THTX stock at a price of $1 per share.
2023-09-20 07:00:00 - GlobeNewsWire
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
MONTREAL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.
2023-09-18 16:15:00 - GlobeNewsWire
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
MONTREAL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2023, on Tuesday, September 26 at 8:30 a.m. EDT.
2023-09-07 13:57:00 - GlobeNewsWire
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MONTREAL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lévesque, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, to be held virtually and in person on September 11-13, 2023, in New York City at the Lotte New York Palace Hotel.
2023-06-29 07:30:00 - GlobeNewsWire
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter ended May 31, 2023, on Wednesday, July 12 at 8:30 a.m. EDT.